ALLK - Allakos: Sad End To A Promising Asset December, 23 2021 12:25 PM Allakos Inc. Lirentelimab's phase 3 failures are spectacular considering the excellent phase 2 data. No one has yet figured out how this went down. However, from every angle, the future of the company looks bleak. For further details see: Allakos: Sad End To A Promising Asset